

1 CLAIMS

2
3 1. A method for producing a vaccine composition
4 containing an immunogenic determinant as the
5 active ingredient, characterised in that the
6 method comprises the steps of:

- 7 a. treating procaryotic cells under
8 conditions such that an increase of the
9 concentration of trehalose within
10 procaryotic cells is induced;
11 b. using the induced cells containing
12 trehalose as the immunogenic determinant
13 in the production of a vaccine
14 composition.

15
16 2. A method as claimed in claim 1, characterised
17 in that the treatment of the procaryotic cells
18 is carried out to achieve a concentration of
19 trehalose within the cells of at least 10mM.

20
21 3. A method as claimed in either of claims 1 or 2,
22 characterised in that the increase in
23 concentration of trehalose is achieved by
24 synthesis of trehalose within the cell.

25
26 4. A method as claimed in any one of the preceding
27 claims, characterised in that the condition
28 causing the increase of trehalose concentration
29 within the cells is heat, osmotic shock,
30 suppression of degradation of trehalose, or
31 genetically engineered constitutive synthesis
32 of trehalose within the cells.

Sub
A1

12-11-2001

12 NOV 01 16:15

From MURGITROD

10049706.041602

+01413078401

T-451 P.05/08 F-487

GB0003223

- Sub
A1
- 1 5. A method as claimed in any one of the preceding
2 claims, characterised in that the induced cells
3 containing the trehalose are dried prior to
4 their use in the production of the vaccine
5 composition.
 - 6
 - 7 6. A method as in claim 5, characterised in that
8 the cells are dried in the absence of added
9 extra-cellular carbohydrate glassy stabilising
10 matrix.
 - 11
 - 12 7. A method as claimed in any one of the preceding
13 claims, characterised in that the procaryotic
14 cells are bacteria, protozoa or fungi.
 - 15
 - 16 8. A method as claimed in any one of the preceding
17 claims, characterised in that the procaryotic
18 cells are treated by cultivating them in a
19 medium containing one or more solutes and
20 having an osmolarity of at least 350 mOsmoles.
 - 21
 - 22 9. A method as claimed in claim 8, characterised
23 in that the solute is selected from a sodium,
24 potassium, calcium and / or ammonium salt.
 - 25
 - 26 10. A method as claimed in claim 1, characterised
27 in that the procaryotic cell has been modified
28 so as to synthesise trehalose.
 - 29
 - 30 11. A method as claimed in claim 1, characterised
31 in that the treatment of the cells is carried

AMENDED SHEET

Emof zeit*12/11/2001 17:08

Emof nr *021 D nns

- 1 out to achieve a concentration of trehalose
2 within the cells of at least 100mM.
3
4 12. A method as claimed in any one of the preceding
5 claims, characterised in that the procaryotic
6 cells containing the induced trehalose are
7 killed prior to use in the vaccine composition.
8
9 13. A method as claimed in any one of the preceding
10 claims, characterised in that the treatment of
11 the procaryotic cells is carried out in vitro.
12
13 14. A vaccine composition comprising an immunogenic
14 determinant, characterised in that the
15 immunogenic determinant includes a procaryotic
16 cell or cell residue which contains at least
17 10mM of trehalose within the cell.
18
19 15. A vaccine composition characterised in that it
20 contains an immunogenic determinant produced by
21 the method of any of claims 1 to 13.
22
23 16. A vaccine composition as claimed in either of
24 claims 14 or 15, characterised in that it
25 contains an adjuvant for the immunogenic
26 determinant.
27
28 17. A vaccine composition as claimed in any one of
29 claims 14 to 16, characterised in that it
30 contains an aqueous carrier.
31

Sub
A1

12-11-2001

12-NOV-01 16:15

From MURGITROV

10049706 .041602

+01413078401

T-451 P.07/08 F-401

GB0003223

- Sub A1
- 1 18. A vaccine composition as claimed in any one of
2 claims 14 to 17, characterised in that the
3 induced cells containing trehalose are dried in
4 the presence of a non-reducing carbohydrate to
5 provide a storage stable but viable immunogenic
6 determinant for storage prior to use in a
7 vaccine composition.
8
- 9 19. The use of a composition as claimed in any one
10 of claims 14 to 18 to immunise an animal.
11
- 12 20. A method for treating an animal with a vaccine,
13 characterised in that a pharmaceutically
14 effective amount of a vaccine composition as
15 claimed in any one of claims 14 to 18 is
16 administered to the animal to elicit an immune
17 response in the animal.
18
- 19 21. A method as claimed in claim 20, characterised
20 in that the vaccine composition is administered
21 by injection.
22
- 23 22. A procaryotic cell which has had its genetic
24 structure modified so as to remove or inhibit
25 that portion of the genetic structure which
26 inhibits or restricts the synthesis of
27 trehalose by the cell whereby the cell
28 constitutively synthesises trehalose within the
29 cell as it grows.
- Sub A2

AMENDED SHEET

Emf mit 12/11/2001 17:02

Emf nr 0021 P 007